PMID- 24527605 OWN - NLM STAT- MEDLINE DCOM- 20150908 LR - 20181202 IS - 1672-173X (Print) IS - 1672-173X (Linking) VI - 45 IP - 1 DP - 2014 Jan TI - [The clinical significance of preoperative enteral immune nutrition in patients with malignant gastrointestinal tumors]. PG - 167-70 AB - OBJECTIVE: To study the impact of preoperative enteral immune nutrition on patients with malignant gastrointestinal tumors. METHODS: 82 patients with malignant gastrointestinal tumors were divided equally into 2 groups:enteral nutrition group (EN) and normal diet group (Control). Enteral Nutritional Emulsion (TPF-T) served as nasogastically-fed liquid diet for the patients in EN group over a period of 7 days prior to surgery. Normal diet was given to the patients in control group under the same condition as those in EN group in terms of calories and nitrogen contents. Enzyme linked immunosorbent assay (ELISA) was performed to determine the quantity of serum albumin (ALB), transferrin protein (TRF), pre-albumin (PA) and retinol binding protein (RBP). Flow cytometry (FCM) was performed to determine T cell subsets. Postoperative complications, resumption of peristalsis, length of hospital stay, and nutritional costs were also recorded. RESULTS: TRF, PA and RBP increased significantly in the patients in EN group compared with those in control group (P < 0.05). The patients in EN group had significantly higher proportions of CD3+, CD4+/CD8+ higher than those of control (P < 0.05). No serious complications (eg. death or gastrointestinal fistula) were found in the patients. The total nutritional cost for the patients in EN group was similar to that of the controls (P > 0.05). The patients in EN group had less postoperative complications, quicker resumption of peristalsis, shorter hospital stay and lower level of postoperative nutrition cost compared with those of controls (P < 0.05). CONCLUSION: Enteral nutrition support can improve the nutritional status and immunity of patients with malignant gastrointestinal tumors, which has both pre-operative and post-operative benefits for the patients. FAU - Huang, Zheng-Jie AU - Huang ZJ AD - Department of Surgical Oncology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China. FAU - Chen, Bai-Sheng AU - Chen BS AD - The First Clinical Medical College, Fujian Medical University, Fuzhou 350004, China. FAU - You, Jun AU - You J AD - Department of Surgical Oncology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China. FAU - Wu, Bing-Lin AU - Wu BL AD - The First Clinical Medical College, Fujian Medical University, Fuzhou 350004, China. FAU - Jiang, Long AU - Jiang L AD - The First Clinical Medical College, Fujian Medical University, Fuzhou 350004, China. FAU - Feng, Qing-Zhao AU - Feng QZ AD - Department of Surgical Oncology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China. FAU - Luo, Qi AU - Luo Q AD - Department of Surgical Oncology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China. LA - chi PT - Controlled Clinical Trial PT - Journal Article PL - China TA - Sichuan Da Xue Xue Bao Yi Xue Ban JT - Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition JID - 101162609 RN - 0 (Retinol-Binding Proteins) RN - 0 (Serum Albumin) RN - 0 (Transferrin) SB - IM MH - *Enteral Nutrition MH - Gastrointestinal Neoplasms/*therapy MH - Humans MH - Length of Stay MH - Nutritional Status MH - Postoperative Complications MH - *Preoperative Care MH - Retinol-Binding Proteins MH - Serum Albumin MH - T-Lymphocyte Subsets MH - Transferrin EDAT- 2014/02/18 06:00 MHDA- 2015/09/09 06:00 CRDT- 2014/02/18 06:00 PHST- 2014/02/18 06:00 [entrez] PHST- 2014/02/18 06:00 [pubmed] PHST- 2015/09/09 06:00 [medline] PST - ppublish SO - Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 Jan;45(1):167-70.